The Samantha Dickson Brain Tumour Trust and Cancer Research UK have teamed up to begin a multicentre Phase II clinical trial for a new surgical technique to treat brain tumours.

The GALA-5 trial being conducted at the University of Cambridge will enrol more than 60 patients with glioblastoma, to examine the tolerability and feasibility of two treatments used in combination.

Patients are due to be given 5-amino-levulinic acid, which causes a build-up of fluorescent chemicals that will make the tumour glow, to allow for more accurate and complete removal.

The second phase of the treatment involves inplanting wafers incorporated with carmustine, a chemotherapy drug, into the cavity to help remove any remaining tumour cells.

The partnership plans to conduct a large Phase III trial if the combination therapy is found to be safe and effective.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.